SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) February 24,
1999
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822
25-1229323
(State of other jurisdiction (Commission File
Number) (IRS Employer
of incorporation)
Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Bioconrol Technology, Inc. has submitted a PMA Shell to
US FDA for its Diasensor 1000 Noninvasive Blood Glucose
Monitor. This outline of modules is necessary to
complete a Premarket Approval Application, the first
step in submission of Modular PMA.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: February 24, 1999
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
BIOCONTROL SUBMITS PMA SHELL TO FDA
Pittsburgh, PA - February 24, 1999 - Biocontrol Technology,
Inc. (OTCBB:BICO) announced today that it has submitted a PMA
Shell to the US Food and Drug Administration (FDA) for its
Diasensor 1000 Noninvasive Blood Glucose Monitor. The PMA Shell
is an outline of those sections or modules that will be necessary
to complete a Premarket Approval Application (PMA) and is the
first step in the company's planned submission of a Modular PMA
for approval to market the Diasensor 1000 in the United States.
Once the PMA shell is approved by the FDA, the company will
submit the first module of the Application for the Diasensor,
which is already approved for the European market.
Biocontrol Technology has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products. Subsidiary
Diasensor.com, Inc., also located in Pittsburgh, PA, markets the
Diasensor. Diasensor.com owns the patent, marketing and
distribution rights to the sensor while Biocontrol has the
exclusive rights to the research and development and
manufacturing of the sensor.
WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1.800.357.6204